Latest Conference Articles

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Combination therapy with datopotamab deruxtecan and rilvegostomig shows significant antitumor activity in advanced urothelial cancer patients.

A phase 2 study reveals lenvatinib and everolimus significantly improve progression-free survival in metastatic clear cell RCC compared to cabozantinib.

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

The OPTIC RCC trial reveals promising outcomes for patients with angiogenic tumors treated with cabozantinib and nivolumab, showcasing high response rates and tumor reduction.

New findings reveal significant PFS benefits of T-DXd plus pertuzumab over traditional therapies for HER2-positive advanced breast cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

Sacituzumab tirumotecan significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer compared to traditional chemotherapy.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

Enfortumab vedotin and pembrolizumab show promising first-line efficacy in treating recurrent metastatic head and neck cancer, with significant response rates.

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

Tislelizumab enhances treatment outcomes in esophageal squamous cell carcinoma, showing improved response rates and survival compared to standard chemoradiotherapy.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Sirexatamab combined with bevacizumab shows promise in improving survival for DKK1-high metastatic colorectal cancer patients, according to recent trial results.

The DREAM3R trial explores durvalumab plus chemotherapy for advanced pleural mesothelioma, revealing promising survival rates despite early study limitations.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.

Adjuvant therapy shows promise in achieving ctDNA clearance in colorectal cancer patients, correlating with improved disease-free survival outcomes.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

Sacituzumab govitecan significantly improves progression-free survival in advanced triple-negative breast cancer, offering a promising alternative to chemotherapy.

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

Gedatolisib enhances progression-free survival in advanced breast cancer patients, showcasing significant benefits when combined with fulvestrant and palbociclib.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.